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Tables and Figures 
Figure 1: Compound 1B exhibits remarkable potency and selectivity against TP53- 
deficient cancer cell lines. 
 
Figure 2: PDE3A is a putative target for Compound 1B inhibition. 
 
Figure 3: Cyclic Nucleotide Phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP 
and/or cGMP and regulate cyclic nucleotide-mediated cell signaling mechanisms. 
 
Figure 4: Structural organization of the PDE superfamily and PDE3 family. 
 
Figure 5: Spatial distribution of Milrinone and Cilostazol bound to the PDE3A catalytic 
site. 
 
Figure 6: Cancer cell lines with varying PDE3A expression levels revealed varying 
sensitivity to Compound 1B in high-throughput screening. 
 
Figure 7: Cancer cell lines with varying PDE3A expression levels exhibit varying 
sensitivity to Compound 1B and validate high-throughput screening results. 
 
Figure 8: Compound 1B sensitive cell lines were rescued in co-treatment with non-lethal 
PDE3 inhibitors. 
 














Synthetic lethal screening of a molecular library discovered Compound 1B, a 
phosphodiesterase 3 (PDE3) inhibitor, to exhibit remarkable potency and selectivity 
against a subset of tumor suppressor TP53-deficient cancer cell lines. High PDE3A 
expression was correlated to Compound 1B sensitivity, thereby suggesting PDE3A as a 
biomarker and putative target for Compound 1B cytotoxicity. High-throughput screening 
results revealed subsets of cancer cell lines that supported the proposed mechanism or 
suggested alternative mechanisms for Compound 1B cytotoxicity. A representative panel 
of cancer cell lines was subjected to Compound 1B treatment to validate previous high-
throughput screening results. Cell lines that were found to be sensitive were subjected to 
analogue treatment in order to evaluate structure-activity relationships. Finally, rescue 
experiments were performed using non-lethal PDE3 inhibitors in order to validate 
PDE3A on target cytotoxicity. Our results validated previous high-throughput screening 
results, suggested Compound 1B and analogues exhibit the same cytotoxic mechanism of 
action, and revealed that competition for PDE3A binding rescued cell death. These 
findings support PDE3A is the target for Compound 1B cytotoxicity, but reveal PDE3A 
is a relatively sensitive and specific biomarker for Compound 1B sensitivity. The 
implications of these findings suggest an unknown dependency exposed through PDE3A 



























Cancer is the leading cause of death worldwide, with 8.2 million deaths reported 
in 2012 1. The multistep development of cancer is characterized by its biological 
hallmarks: genomic instability, inflammation, sustained proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis, reprogramming energy metabolism, 
evading immune destruction, and creating a tumor microenvironment which fosters 
acquisition of hallmarks traits 2. The development of cancer therapies has evolved from 
general cytotoxic chemotherapies to molecule-specific targeted therapies, which interfere 
with specific oncogenic pathways characteristic to a tumor genotype and provide a 
personalized approach to cancer therapy 3. However, the complexity of cancer 
development presents a challenge for the development of personalized cancer therapies, 
as each oncogenic phenotype exhibits particular biological characteristics that 
differentiate in clinical behavior and response to treatment 4–7. Challenges include the 
identification of molecular targets essential for cancer maintenance. Additional 
limitations include the identification of clinically useful biomarkers to diagnose the 
disease state, select an appropriate therapeutic regimen, and monitor the progression of 
the disease. The continuous investigation and understanding of cancer pathogenesis has 
allowed for the discovery and development of targeted drugs that exploit the genetic 
dependencies of cancer, and provide personalized cancer therapies with improved 
treatment efficacy and reduced toxicity 8,9. 
Synthetic lethal screening of a molecular library discovered Compound 1B to 
exhibit remarkable potency (EC50 < 100 nM) and selectivity against a subset of tumor 
! 7!
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suppressor TP53 deficient cancer cells lines, while being inactive against other cell lines, 
including immortalized but nontumorigenic cell lines (Figure 1). A Pearson correlation 
revealed a strong positive correlation for Phosphodiesterase 3A (PDE3A) and suggested 
PDE3A is a biomarker for Compound 1B sensitivity (Figure 2A) 10. Screening for 
phosphodiesterase inhibitory activity revealed Compound 1B is a selective 
Phosphodiesterase 3 (PDE3) inhibitor, thereby suggesting PDE3A as the putative target 
for Compound 1B cytotoxicity (Figure 2B). Phosphodiesterases (PDEs) are enzymes that 
regulate intracellular concentrations of signal transduction molecules, cyclic adenosine 
and guanine 3',5' monophosphate (cAMP and cGMP), and mediates nucleotide-dependent 
cell signaling mechanisms 11,12. The therapeutic success of PDE inhibition has been 
recognized, as observed in the treatment of erectile dysfunction, pulmonary hypertension, 
acute refractory cardiac failure, and intermittent claudication 13–16. However, the potential 
of PDE inhibition for cancer treatment remains under investigation. The lack of isoform-
selective PDE inhibitors and the limited knowledge on the roles of PDEs in cancer 
development reveal some of the challenges in targeting PDEs for therapeutic purposes 















Figure' 1.' Compound' 1B'exhibits' remarkable' potency' and' selectivity' against'TP53<deficient' cancer' cell'
lines.' (A)' Structure'of'Compound'1B.' (B)'Dose4response'curve'of'Compound'1B' for'32' cancer' cell' lines.'
Compound' 1B' exhibited' nanomolar' activity' against' TP534deficient' cell' lines,' H1563,' H1734,' H2122' and'
HeLa,'but'not'TP53'wild4type'cell'lines'and'other'cell'lines. '
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cytotoxicity is significant, as it reveals an unknown role of PDE3A in cancer 
development and suggests the prospects of targeting PDE3A for cancer treatment. 
PDEs are enzymes that catalyze the hydrolytic cleavage of the cyclic nucleotide 
3’,5’ phosphodiester bond to form the corresponding inactive 5’-monophosphate, such 
that PDE activity decreases intracellular cyclic nucleotide levels, and regulate the 
amplitude and duration of the nucleotide-dependent signaling pathways (Figure 3A) 11,12. 
PDEs    regulate    cyclic    nucleotide    gradients    within    signaling    complexes    that 
compartmentalize unique combinations of PDEs with signaling effectors, such as Protein 
Kinase A (PKA), Protein Kinase G (PKG), cAMP-activated exchange factors (EPAC), 
and cyclic nucleotide-gated ion channels (CNG), and mediate protein-protein interactions 
for nucleotide-dependent signaling cascades (Figure 3B) 19–22. Examples of cell signaling 
responses include cellular proliferation, differentiation, apoptosis, inflammation, and 
vasodilation (Figure 3B) 23–25. The PDE family is comprised of 11 members that share 
similar structural characteristics but exhibit distinct physiological roles, tissue expression 
Figure' 2.' Phosphodiesterase' 3A' is' a' putative' target' for' Compound' 1B' inhibition.' (A)' A' Pearson'



















patterns, subcellular locations, regulatory properties, and enzymatic properties 24–26. The 
PDE family is comprised of 21 genes and multiple transcriptional products that result 
from alternative splicing or transcription from different start sites 21. The structural 
organizations of PDEs share the following characteristics: a C-terminal HD domain that 
shows high affinity for cAMP and/or cGMP; a highly conserved catalytic domain; and 
lastly, highly variable N-terminal regulatory protein domains that regulate PDE 
enzymatic activity and subcellular localization characteristic to each PDE family (Figure 
4A) 18,21. The PDE catalytic domains constitute 16 α-helices that form an active-site 
pocket characterized by highly conserved hydrophobic residues and two conserved metal-




cleavage' of' the' 3'' phosphodiester' bond' of' the' cyclic' adenosine' and/or' guanosine' 3',5'' cyclic'
monophosphate' (cAMP' and/or' cGMP,' respectively),' resulting' in' the' formation' of' the' corresponding'

















































with a water molecule or hydroxide ion that acts as a nucleophile in the hydrolytic 
cleavage of the cyclic nucleotide phosphodiester bond by PDE 29,30. In addition to cyclic 
nucleotide hydrolysis, the functional roles of PDEs as scaffold proteins or exhibiting 
allosteric regulation to alter protein complex formation and mediate signal transduction 
pathways have been previously investigated 17.  
The PDE3 family is characterized by its biochemical ability to hydrolyze both 
cAMP and cGMP with high affinities (Km cAMP <0.4 μM; Km cGMP <0.3 μM) 31,32. A 
unique characteristic of the PDE3 family is the presence of a 44-amino acid insert in the 
catalytic domain, which constitutes a flexible loop on the surface of the enzyme that 














following' structural' characteristics:' a' C4terminal' HD'domain' (shown' in' blue)'with'high'affinity' for' cAMP'
and/or' cGMP;' a' highly' conserved' catalytic' domain' (shown' in' teal);' and,' highly' variable' N4terminal'
regulatory'protein'domains'(Lugnier,'2006).'(B)'The'PDE3'family'is'comprised'of'three'PDE3A'that'differ'in'
their'N4terminal'portions:'PDE3A1'contains'membrane'association'domains'NHR1'and'NHR2,'and'PKB'(P1),'





The PDE3 family consists of two genes: PDE3A, which is highly expressed in platelets 
and cardiac tissue, and PDE3B, which is expressed in hepatocytes and adipose tissue 34. 
PDE3A and PDE3B share a similar structural organization but exhibit divergent N-
terminal regulatory protein domains, including membrane-association domains NHR1 
and NHR2, which target for subcellular localization, and phosphorylation sites for 
Protein Kinase A (PKA), Protein Kinase B (PKB) and Protein Kinase C (PKC), which 
regulate PDE enzymatic activity 35,36. Three PDE3A isoforms that result from alternative 
translation initiation sites within a single PDE3A gene have been identified 37. The three 
PDE3A variants differ in their N-terminal regulatory sequences: PDE3A1, which is 
localized to the intracellular membranes, contains membrane-association domains NHR1 
and NHR2, and three sites of phosphorylation by PKA, PKB, and PKC; PDE3A2, which 
is localized to both membranes and cytosol, contains NHR2 and two sites of 
phosphorylation by PKA and PKC; and lastly, PDE3A3, which is localized to the cytosol, 
lacks both NHR1 and NHR2, and all three phosphorylation sites (Figure 4B) 36,38,39. The 
three PDE3A variants exhibit very similar catalytic activities and sensitivity to PDE3 
inhibitors 39,40 . 
The development of PDE3 inhibitors has facilitated the investigation of the roles 
of PDE3 in regulating important cyclic nucleotide-mediated processes, including 
myocardial contractility, platelet aggregation, vascular and airway muscle relaxation, 
oocyte maturation, and inflammation 17,21,41. PDE3 selective inhibitors include Trequinsin, 
Milrinone, Cilostazol, and Cilostamide (Supplementary Appendix, Table S1). Milrinone 
(Primacor ®) and Cilostazol (Pletal ®) are well characterized PDE3 inhibitors and are 
therapeutically used in the treatment of heart failure and intermittent claudication due to 
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their antiaggregant and vasolidator properties 16,42–44. The binding of Milrinone or 
Cilostazol to a PDE3A model indicates that specific hydrogen bond interactions between 
the inhibitor and an invariant glutamine are required for substrate recognition and 
selectivity, while a planar ring structure for the inhibitor to be held tightly within the 
active site by the hydrophobic clamp is required for substrate binding (Figure 5A for 
Milrinone; Figure 5B for Cilostazol) 27,28,45. A comparison of the spatial distributions of 
cAMP and Cilostazol bound to the PDE3A active site suggests a portion of the Cilostazol 
molecule is exposed towards the exterior of the active site pocket, which may introduce a 
new interface to the surface of the enzyme (Figure 5C). The mechanism for PDE 
inhibition has been suggested to include other functional possibilities, beyond the 
inhibition of nucleotide hydrolysis, such as: obstruction of enzyme dimerization, 
inhibition of phosphorylation, or interference with allosteric activation or regulation, 











Figure' 5.' Spatial' distribution'of'Milrinone' and' Cilostazol' bound' to' the' PDE3A' catalytic' site.'Molecular'
modeling' of' the' PDE3A' active' site' illustrates' the' binding' of' PDE3' selective' inhibitors,' Milrinone' and'
Cilostazol,'to'the'PDE3A'catalytic'site'(Zhang'et'al.,'2001).'PDE3A'residues'involved'in'binding'are'labeled.'
(A)' Milrinone' and' (B)' Cilostazol' are' represented' by' large' balls;' green,' carbon' atom;' red,' oxygen' atom;'
blue,' nitrogen'atom.' (C)'A' comparison' of' the' spatial' distributions'of'bound'cAMP,' represented' as' small'






The molecular mechanism involved in the potency and selectivity for Compound 
1B cytotoxicity remains unknown. HTS results revealed subsets of cancer cell lines that 
supported contradictory mechanisms: high PDE3A sensitive cell lines support PDE3A as 
the target for cytotoxicity; low PDE3A sensitive cell lines suggest a non-specific 
cytotoxic mechanism; and, high PDE3A insensitive cell lines suggest PDE3A is required 
but not sufficient for Compound 1B cytotoxicity (Figure 6). Furthermore, the distinction 
of non-lethal PDE3 inhibitors, Trequinsin and Cilostamide, and lethal PDE3 inhibitors 
structurally related to Compound 1B, Zardaverine and Anagrelide, indicates Compound 
1B cytotoxicity is not dependent on its inhibition of PDE3 cyclic nucleotide hydrolysis 
and suggests a specific structural characteristic of Compound 1B may be responsible for 
mediating the cytotoxic effects. A representative panel of high and low PDE3A 
expressing, Compound 1B sensitive and insensitive cancer cell lines were used in this 
study to validate HTS results, characterize the sensitivity and specificity of PDE3A as a 
biomarker, and further investigate PDE3A on target cytotoxicity. 
 





























Materials and Methods 
Cell Line and Culture Condition. Lu-65 (HSRRB, Lu-65 JCRB0079), HuT-78 (ATCC, 
HuT-78 CRM-TIB-161), RVH-421 (RIKEN, RVH-421 ACC127), ML-1 (DSMZ, ML-1 
ACC464) and MHH-NB-11 (DSMZ, MHH-NB-11 ACC157) were cultured in RPMI-
1640 with L-glutamine (Corning, 10-040-CV). COV-318 (ECACC, COV-318 
07071803), CAS-1 (ICLC, CAS-1 HTL97009), and L3.3 (Academic Laboratory) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, 11995-065). JHOM-1 
cells (RIKEN, JHOM-1 RCB1676) were cultured in a 1:1 nutrient mixture of DMEM and 
Ham’s F12 (Gibco, 11765-047) and 1% HyClone non-essential amino acids (NEAA; 
Fisher Scientific, SH40003-12). G-631 cells (ATCC, G-361 CRL-1424) were cultured in 
McCoy’s 5A (modified) medium (Gibco, 16600-082). 8505C cells (HSRRB, 8505C 
JCRB0826) were cultured in Eagle’s Minimal Essential Medium α (EMEM; Gibco, 
A10490-01) supplemented with 1% HyClone NEAA. All media were supplied with 10% 
Fetal Bovine Serum (FBS; Sigma F4135) and 1% Penicillin-Streptomycin-Glutamine 
(Pen-Strep-Glut; Gibco, 10378-016).  All cell lines were cultured in tissue culture flasks 
of 75 cm2 with their corresponding media and supplements, and were maintained at 37°C 
in a 5% CO2 humidified incubator.  
Cell-growth Parameters. All cell lines were grown to 90% confluence and counted in a 
Beckman Coulter Vi-CELL cell viability analyzer with a trypan blue dye exclusion 
method. The cells were plated at densities ranging from 500 to 5,500 cells per well, with 
500 cells per well increments, in a Corning® 384-well plate (Sigma, CLS3570BC) in 40 
µL of the corresponding growth medium.  The 384-well plate was incubated for 72 hours 
at 37°C in a 5% CO2 humidified incubator. After 72 hours of incubation, the 384-well 
! 15!
plate was removed from the incubator and allowed to cool to room temperature for 30 
minutes. Cell viability was assessed by adding a 1:1 mixture of 25% CellTiter-Glo® 
(Promega, G7570), diluted with room temperature Phosphate Buffer Saline (PBS; 
Corning, 21-040-CV), to each well in the 384-well plate, incubating for ten minutes at 
room temperature, and measuring the luminescence signal on a PerkinElmer EnVision® 
with US LUM settings for 0.1 second per well.  Cell-growth data was subjected to non-
linear regression curve analysis using the GraphPad™ Prism ® v6.0 Software (GraphPad 
Software, La Jolla, USA) in order to determine the optimal cell density for cytotoxic 
assessment.  
Compound 1B and Analogues Treatment. All cell lines were grown to 90% confluence 
and counted in a Beckman Coulter Vi-CELL cell viability analyzer with a trypan blue 
dye exclusion method. Cytotoxicity assays were performed at the optimal cell density for 
each cell line, that is, the cell density at the peak of the exponential growth curve but 
prior to pre-plateau growth phase. The following cell densities were used for the 
cytotoxic screening: 2000 8505C cells, 1500 CAS-1 cells, 3500 COV-318 cells, 2500 G-
361 cells, 3000 HuT-78 cells, 4000 JHOM-1 cells, 1500 L3.3 cells, 3000 Lu-65 cells, 
3500 MHH-NB-11 cells, 3000 ML-1 cells, and 2500 RVH-421 cells per well. The 
specific cell density per each cell line was plated in a 384-well plate in 40 µL of the 
corresponding growth medium and incubated for 24 hours at 37°C in a 5% CO2 
humidified incubator. Compound 1B (Enamine, T0503-7331), or synthesized analogues, 
TP7, TP26, or TP51, were added with final concentrations ranging from 300 pM to 10 
µM using a medium intermediate dilution. The 384-well plate was incubated for 48 hours 
at 37°C in a 5% CO2 humidified incubator. After 48 hours of incubation, the 384-well 
! 16!
plate was removed from the incubator and allowed to cool to room temperature for 30 
minutes. Cell viability was assessed by adding a 1:1 mixture of 25% CellTiter-Glo®, 
diluted 1:3 with room temperature PBS, to each well in the 384-well plate using a Rainin 
multichannel pipette, incubating for ten minutes at room temperature, and measuring the 
luminescence signal on a PerkinElmer EnVision® with US LUM settings for 0.1 second 
per well. Luminescence units were normalized to percent of maximum proliferation. 
Dose-response data was subjected to non-linear regression curve analysis using the 
GraphPad™ Prism ® v6.0 Software. The mean EC50 was calculated for each compound 
in each cell line using GraphPad™ Prism ® v6.0 Software. EC50 is defined as the drug 
concentration required for 50 percent of maximum effect, that is, the halfway point 
between the baseline and the maximum response observed for the dose-response curves. 
Refer to Supplementary Appendix, Methods S1 for the detailed cytotoxicity assay 
protocols.  
Compound 1B and PDE3 Inhibitor Co-Treatment. Compound 1B sensitive cell lines, 
8505C, CAS-1, HuT-78, JHOM-1, L3.3, and RVH-421, were subjected to Compound 1B 
and non-lethal PDE3 inhibitor co-treatment. Inhibitor co-treatment was performed at the 
optimal cell density previously determined for each cell line, that is, the cell density at the 
peak of the exponential growth curve but prior to pre-plateau growth phase. The 
following cell densities were used for the inhibitor co-treatment: 2000 8505C cells, 1500 
CAS-1 cells, 3000 HuT-78 cells, 4000 JHOM-1 cells, 1500 L3.3 cells, and 2500 RVH-
421 cells per well. The specific cell density per each cell line was plated in a 384-well 
plate in 40 µL of the corresponding growth medium and was allowed to incubate for 24 
hours at 37°C in a 5% CO2 humidified incubator. After 24 hours of incubation, 
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Trequinsin (VWR, 80058-202) or Cilostamide (Sigma Aldrich, C7971) were added in 
concentrations ranging from 0.3 nM to 10 µM using a medium intermediate dilution 
containing the EC90 of Compound 1B observed in the cytotoxic screening per each 
sensitive cell line. EC90 is defined as the drug concentration required for 90 percent of 
maximum effect, as observed for dose-response curves. The 384-well plate was allowed 
to incubate for 48 hours at 37°C in a 5% CO2 humidified incubator. After 48 hours of 
incubation, the 384-well plate was removed from the incubator and allowed to cool to 
room temperature for 30 minutes. Cell viability was assessed by adding a 1:1 mixture of 
25% CellTiter-Glo®, diluted 1:3 with room temperature PBS, to each well in the 384-
well plate using a Rainin multichannel pipette, incubating for ten minutes at room 
temperature, and measuring the luminescence signal on PerkinElmer EnVision® with US 
LUM settings for 0.1 second per well. Luminescence units were normalized to percent of 
maximum proliferation and cell line sensitivity was determined by a non-linear 
regression curve analysis. Refer to Supplementary Appendix, Methods S2 for the detailed 



















Cancer cell lines with varying PDE3A expression levels and sensitivity to 
Compound 1B were studied in order to evaluate PDE3A as a biomarker and target for 
Compound 1B cytotoxicity. A strong correlation for PDE3A expression in Compound 1B 
sensitive cell lines and the identification of Compound 1B as a selective PDE3 inhibitor 
suggested PDE3A as the putative target for Compound 1B cytotoxicity (Figure 2). HTS 
for Compound 1B cytotoxicity revealed high PDE3A expressing sensitive cell lines that 
support the proposed mechanism, as well as high PDE3A insensitive cell lines and low 
PDE3A sensitive cell lines that suggest alternative mechanisms (Figure 6). A 
representative panel of cell lines were investigated in this study: high PDE3A expressing, 
Compound 1B sensitive cell lines JHOM-1 and L3.3; high PDE3A expressing, 
Compound 1B insensitive cell lines ML-1, Lu-65, MHH-NB-11, and G-361; and, low 
PDE3A expressing, Compound 1B sensitive cell lines 8505C, CAS-1, HuT-78, RVH-
421, and COV-318.  All cell lines used in this study are characterized in the Cancer Cell 
Line Encyclopedia (CCLE) 10. Cell-growth parameters for each cell line were evaluated 
using non-linear regression curve analysis in order to determine the optimal cell density 
for cytotoxic assessment (Supplementary Appendix, Figure S1). The optimal cell 
densities used for this study are indicative of the cell culture density at which the 
exponential cell growth curve peaks, prior to the pre-plateau growth phase, for each cell 
line. Drug treatments were performed at the optimized cell density in order to maximize 
the dynamic range for the cytotoxicity assay and accurately evaluate drug-induced effects 
from cell viability dose-response curves.  
! 19!
 All cell lines were subjected to Compound 1B treatment in order to validate 
previous results obtained in HTS results for Compound 1B cytotoxicity and evaluate 
PDE3A as a biomarker for sensitivity. High PDE3A expressing cell lines, JHOM-1 and 
L3.3, revealed sensitivity to Compound 1B in HTS and supported the proposed 
mechanism of PDE3A as the target for Compound 1B cytotoxicity (Figure 7A). JHOM-1 
and L3.3 exhibited sensitivity to Compound 1B treatment and validated HTS results 
(Figure 7B). JHOM-1 and L3.3 support PDE3A as the target for Compound 1B 
cytotoxicity. Low PDE3A expressing cell lines, 8505C, CAS-1, HuT-78, RVH-421 and 
COV-318, revealed sensitivity to Compound 1B in HTS, thereby suggesting an 
alternative mechanism for Compound 1B cytotoxicity (Figure 7A). 8505C, CAS-1, HuT-
78, and RVH-421 exhibited sensitivity to Compound 1B treatment and validated HTS 
results. COV-318, however, did not exhibit sensitivity to Compound 1B treatment and 
was the only cell line to contradict HTS results (Figure 7C). High PDE3A expressing cell 
lines, ML-1, Lu-65, MHH-NB-11, and G-361, did not reveal sensitivity to Compound 1B 
in HTS, thereby suggesting an alternative mechanism for Compound 1B cytotoxicity 
(Figure 7A). ML-1, Lu-65, MHH-NB-11, and G-361 did not exhibit sensitivity to 
Compound 1B treatment, thereby validating HTS results (Figure 7D). All cancer cell 
lines subjected to Compound 1B treatment supported HTS results, with the exception of 
COV-318, thereby indicating the validity of HTS results. An evaluation of PDE3A as a 
biomarker reveals PDE3A is relatively sensitive and specific biomarker for Compound 
1B sensitivity. Sensitivity is defined as the percentage of true-positive results, that is, the 
percentage of Compound 1B sensitive cell lines that exhibit high PDE3A expression, 
whereas specificity is defined as the percentage of true-negative results, that is, the 
! 20!
percentage of low PDE3A expressing cell lines that did not exhibit Compound 1B 
sensitivity. PDE3A exhibits 23.5% sensitivity and 98.7% specificity as a biomarker, as 
23.5% of sensitive cell lines exhibited high PDE3A expression levels while 98.7% of 
insensitive cell lines exhibited low PDE3A expression levels  (Figure 7A).  However, 
PDE3A sensitivity is relative based on the PDE3A expression levels that serve as the 
standards to predict for Compound 1B sensitivity. Our findings indicate PDE3A is not a 













































































In order to investigate cytotoxic activity, Compound 1B sensitive cell lines were 
subjected to analogue treatment to evaluate structure-activity relationships. Structure-
activity analysis was performed using three analogues with stronger, intermediate, and 
weak potencies in order to validate their activities and compare their cytotoxic behaviors 
across all cancer cell lines. Potency is inversely related to the EC50 value, such that a 
lower EC50, or drug concentration required for 50 percent of maximum effect, is 
indicative of a stronger potency. The following analogues were used, in their order of 
potency as observed for HeLa cells: TP51 > Compound 1B > TP26 > TP7 (Table 1). 
High PDE3A expressing cell lines, JHOM-1 and L3.3, and low PDE3A expressing cell 
lines, 8505C, CAS-1, HuT-78, and RVH-421, were subjected to TP51, TP26, and TP7 
treatment and exhibited sensitivity (Supplementary Appendix, Figure S2). Structure-
activity analysis indicated Compound 1B and analogues exhibit the same potency or EC50 
trend for all cell lines and did not reveal off-target activities (Table 1). These findings 
suggest Compound 1B and analogues exhibit a similar mechanism of action for 






HeLa' 1'nM' 10'nM' 30'nM' >'10'µM'
JHOM41' 8'nM' 40'nM' 102'nM' >'1'µM'
L3.3' 9'nM' 42'nM' 63'nM' >'1'µM'
RVH4421' 5'nM' 30'nM' 32'nM' >'1'µM'
CAS41' 12'nM' 35'nM' 143'nM' >'1'µM'
HuT478' 24'nM' 47'nM' 134'nM' >'1'µM'















Lastly, to evaluate PDE3A on target cytotoxicity, a rescue experiment was 
performed using non-lethal PDE3 inhibitors, Trequinsin and Cilostamide, to compete 
against Compound 1B for binding at the PDE3A catalytic site. Previous experiments 
revealed PDE3 inhibitors Trequinsin and Cilostamide did not exhibit lethal effects 
against HeLa cells, and thus are referred to as “non-lethal” PDE3 inhibitors, whereas 
Zardaverine, which is structurally related to Compound 1B, exhibited lethal effects (Data 
not shown). Compound 1B sensitive cell lines were subjected to a drug co-treatment 
using the EC90 of Compound 1B, as determined for each cell line, and increasing 
concentrations of Trequinsin or Cilostamide in order to evaluate cell viability effects 
resulting from competition for binding at the PDE3A catalytic site. EC90 is defined as the 
Compound 1B concentration required for 90 percent of maximum effect, as determined 
from dose-response curves for each cell line. High PDE3A expressing cell lines, JHOM-1 
and L3.3, and low PDE3A expressing cell lines, 8505C, CAS-1, HuT-78, and RVH-421, 
were rescued in co-treatment with Trequinsin or Cilostamide (Figure 8; Supplementary 


















lines' were' subjected' to' drug' co4treatment' using' the' EC90' of' Compound' 1B' corresponding' to' each' cell' line,' and'
increasing'concentrations'of'Trequinsin'and'Cilostamide'(0.3'nM'4'10'µM)'for'48'hours.'EC90' is'defined'as'the'drug'
concentration' required' for' 90' percent' of'maximum'effect,' as' determined' from'dose4response' curves' for' each' cell'
line.''Error'bars'represent'S.D.'of'mean,'n'='16'replicates.' ' (A)'L3.3'was'rescued'in'co4treatment'with'Compound'1B'
and' Trequinsin.' JHOM41,' RVH4421,' CAS41,' HuT478,' and' 8505C' exhibited' rescue' at' 0.3' nM' Trequinsin.' (B)' 8505C,'












































cytotoxicity, as competition with non-lethal PDE3 inhibitors against Compound 1B for 
binding at the PDE3A catalytic site rescued cell death. Furthermore, these results reveal 
Compound 1B cytotoxicity is not dependent upon its inhibition of PDE3 cyclic 
nucleotide hydrolysis, as other PDE3 inhibitors do not exhibit cytotoxic effects.  
The validation of HTS results revealed PDE3A exhibits relative sensitivity and 
specificity as a biomarker. Our findings indicate PDE3A exhibits 23.5% sensitivity and 
98.7% specificity as a biomarker and suggest PDE3A is not a good predictive biomarker 
for Compound 1B sensitivity. Despite its limitations, PDE3A is the only known 
biomarker for Compound 1B cytotoxicity. Structure-activity analysis indicated 
Compound 1B and analogues exhibit similar cytotoxic activities, thereby suggesting 
Compound 1B and analogues exhibit the same cytotoxic mechanism of action in sensitive 
cell lines. Rescue experiments with non-lethal PDE3 inhibitors revealed that competition 
against Compound 1B for binding at the PDE3A catalytic site rescues cell death, thereby 
revealing PDE3A is the target for Compound 1B cytotoxicity. In summary, these findings 
support PDE3A is the target for Compound 1B cytotoxicity, but indicate PDE3A is 










 An evaluation of PDE3A as a biomarker for Compound 1B sensitivity revealed 
PDE3A is relatively sensitivity and is specific as a biomarker for Compound 1B 
sensitivity. The proposed mechanism for Compound 1B cytotoxicity suggested PDE3A 
as the target; however, the validation of HTS results suggested the possibility of 
alternative mechanisms, based on PDE3A expression and sensitivity to Compound 1B. 
Structure-activity analysis and competition for Competition for PDE3A binding 
confirmed PDE3A on target cytotoxicity and revealed Compound 1B cytotoxicity is not 
dependent on the inhibition of PDE3A catalytic activity.  These results suggest PDE3A is 
a potential therapeutic target for anticancer therapy, but suggest PDE3A is not a good 
predictive biomarker for sensitivity and may not be clinically useful, on its own, for 
biomarker-based patient selection.   
 PDE3A is the only identified biomarker for Compound 1B sensitivity and exhibits 
relative sensitivity and specificity to predict for Compound 1B sensitivity. Even though 
PDE3A is not an ideal biomarker, PDE3A is a biomarker that can be further evaluated for 
drug development and clinical trials. The significance of predictive biomarkers as 
companions of targeted drugs is illustrated in the cases of targeted drugs Imatinib 
(Gleevec®) and Erlotinib (Tarceva®). Imatinib, a tyrosine kinase inhibitor, was 
specifically designed to inhibit the kinase activity of BCR-ABL, a translocation protein 
found in 95% of chronic myeloid leukemia (CML) 47,48. The discovery of BCR-ABL as a 
predictive biomarker allowed for biomarker-based patient selection in clinical trials, 
which facilitated the proof of imatinib clinical benefit for CML 49. The case of imatinib 
reflects the prospects of PDE3A as a relevant biomarker for drug development. The case 
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of erlotinib, however, reflects limitations of biomarkers. Erlotinib is an inhibitor of 
tyrosine kinase activity in epidermal growth factor receptor (EGFR) used for the 
treatment of non-small cell lung cancer (NSCLC) 50. Even though EGFR overexpression 
was initially a candidate predictive biomarker, EGFR overexpression was not a consistent 
biomarker and, overall, did not correlate erlotinib sensitivity 51. A recent study indicated 
EGFR overexpression exhibited 63.4% sensitivity and 76.8% specificity as a biomarker 
for erlotinib sensitivity 52. Even though PDE3A is more specific as a biomarker than 
EGFR overexpression, PDE3A is not a very sensitive biomarker and may not be useful, 
on its own, for clinical trials. PDE3A should be further investigated to evaluate the 
cytotoxic mechanism attributed to PDE3A inhibition and characterize downstream 
biomarkers to predict clinical response or with the potential to serve as therapeutic 
targets.  
PDE3A was identified as the target for Compound 1B cytotoxicity. However, the 
specific PDE3A isoform responsible for mediating the cytotoxic effects of Compound 1B 
remains unknown. Compound 1B and analogues are presumed to target all PDE3A 
isoforms, which exhibit indistinguishable sensitivity to PDE3 inhibitors 39. The three 
PDE3A isoforms, PDE3A1, PDE3A2, and PDE3A, are identical except for different 
lengths of their N-terminal regulatory sequences and distribution of membrane-
association domains, which target for intracellular location, and phosphorylation sites, 
which regulate protein-protein interactions and catalytic activities. Recent studies 
indicated PDE3A1 and PDE3A2 are phosphorylated at alternative sites via different 
signaling pathways and exhibit distinct protein-protein interactions, thereby suggesting 
PDE3A1 and PDE3A2 exhibit distinct roles in regulating cyclic nucleotide signaling 36. 
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Even though Compound 1B and analogues are proposed to target all three PDE3A 
variants, the PDE3A isoform responsible for mediating the cytotoxic effects remains 
unknown. Even though Compound 1B is proposed to target all three PDE3A variants, our 
findings indicate that Compound 1B does not exhibit its cytotoxic effects via its 
inhibition of PDE3A cyclic nucleotide hydrolysis, as non-lethal PDE 3 inhibitors 
competed for PDE3A binding and rescued cell death.  
 The discovery of PDE3A as a biomarker and target for Compound 1B 
cytotoxicity is significant as it reveals an unknown role for PDE3A in cancer 
development and suggests the prospects of targeting PDE3A for cancer treatment. 
Compound 1B sensitivity is not lineage-specific, thereby suggesting Compound 1B 
exhibits its cytotoxic effects by interfering with a specific pathway necessary for cancer 
development across all sensitive cell lines. The identification of non-lethal PDE3 
inhibitors and lethal PDE3 inhibitors structurally related to Compound 1B suggests 
cytotoxicity is independent of PDE3 inhibition of catalytic activity and may dependent 
upon a specific structural characteristic of Compound 1B. A recent study indicated 
Zardaverine, a dual PDE3/4 inhibitor structurally related to Compound 1B, revealed 
potent and selective antitumor activity against hepatocellular carcinoma (HCC) 
independently of PDE3/4 inhibition 53. These findings support Zardaverine as a lethal 
PDE3 inhibitor and suggest cytotoxicity may be dependent on a structural characteristic 
of Zardaverine, as proposed for Compound 1B. The possibilities for Compound 1B 
cytotoxicity include alterations in protein-protein interactions that affect signaling 
cascades and disruption of PDE cross-talk or pharmacodynamics, such that the cytotoxic 
effects of PDE3A inhibition may mediated via the alteration of regulation or indirect 
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inhibition of another PDE within the same compartment 26,54. The implications of these 
findings support an unknown role for PDE3A in cancer development and indicate 
PDE3A is a potential target for anticancer therapies. The mechanisms for Compound 1B 
cytotoxicity should be further investigated to characterize the effects of Compound 1B in 
PDE3A regulation of protein interactions or identify downstream predictive biomarkers 
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Supplementary Appendix, Figure S2: Compound 1B and analogue treatment cell 
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Supplementary Appendix, Methods S1: Detailed Cytotoxicity Assay Protocols 
 
8505C cytotoxicity assay using CellTiter-Glo® 
Day 0: 8505C cells (HSRRB, 8505C JCRB0826) are grown to 90% confluence in 
EMEM, 1% NEAA, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (2000 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
CAS-1 cytotoxicity assay using CellTiter-Glo® 
Day 0: CAS-1 cells (ICLC, CAS-1 HTL97009) are grown to 90% confluence in DMEM, 
10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (1500 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
COV-318 cytotoxicity assay using CellTiter-Glo® 
Day 0: COV-318 cells (ECACC, COV-318 07071803) are grown to 90% confluence in 
DMEM, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (3500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
! 3!
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
G-361 cytotoxicity assay using CellTiter-Glo® 
Day 0: G-631 cells (ATCC, G-361 CRL-1424) are grown to 90% confluence in McCoy’s 
5A, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (2500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
HuT 78 cytotoxicity assay using CellTiter-Glo® 
Day 0: HuT 78 cells (ATCC, HuT 78 CRM-TIB-161) are grown to 90% confluence in 
RPMI-1640, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (3000 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 




JHOM-1 cytotoxicity assay using CellTiter-Glo® 
Day 0: JHOM-1 cells (RIKEN, JHOM-1 RCB1676) are grown to 90% confluence in 
DMEM, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (4000 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
L3.3 cytotoxicity assay using CellTiter-Glo® 
Day 0: L3.3 cells (Academic Laboratory) are grown to 90% confluence in DMEM, 10% 
FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (1500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with a Rainin multichannel pipette and incubate for 10 
minutes at room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 
0.1 second per well.  
 
LU65 cytotoxicity assay using CellTiter-Glo® 
Day 0: LU65 cells (HSRRB, LU65 JCRB0079) are grown to 90% confluence in 1:1 
DMEM and Ham’s F12, 1% NEAA, 10% FBS, 1% Pen-Strep-Glut.  
Day 1: Plate cells (3000 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
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well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
MHH-NB-11 cytotoxicity assay using CellTiter-Glo® 
Day 0: MHH-NB-11 cells (DSMZ, MHH-NB-11 ACC157) are grown to 90% confluence 
in RPMI-1640, 10% FBS, 1% Pen-Strep-Glut.  
Day 1: Plate cells (3500 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
ML-1 cytotoxicity assay using CellTiter-Glo® 
Day 0: ML-1 cells (DSMZ, ML-1 ACC464) are grown to 90% confluence in RPMI-
1640, 10% FBS, 1% Pen-Strep-Glut.  
Day 1: Plate cells (3000 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 




RVH-421 cytotoxicity assay using CellTiter-Glo® 
Day 0: RVH-421 cells (RIKEN, RVH-421 ACC127) are grown to 90% confluence in 
RPMI-1640, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (2500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Compound 1B, TP7, TP26, and TP51 using a serial dilution to 
obtain concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media, and further dilute 1:5 by adding 10 μL of drug into the designated 40 μL plated 
well (50 μl total volume). Perform at least 8 replicates per concentration per drug. The 
final dilution will be 1000x (10 μM – 0.3 nM).  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 































Supplementary Appendix, Methods S2: Detailed Co-Treatment Assay 
Protocols 
 
8505C co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: 8505C cells (HSRRB, 8505C JCRB0826) are grown to 90% confluence in 
DMEM, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (2000 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 100 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 100 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
CAS-1 co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: CAS-1 cells (ICLC, CAS-1 HTL97009) are grown to 90% confluence in DMEM, 
10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (1400 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 100 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 100 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 





HuT-78 co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: HuT-78 cells (ATCC, HuT 78 CRM-TIB-161) are grown to 90% confluence in 
DMEM, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (3000 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 300 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 300 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
JHOM-1 co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: JHOM-1 cells (RIKEN, JHOM-1 RCB1676) are grown to 90% confluence in 
DMEM, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (4000 cells per well) in 40 μl of culturing media using Corning® 384-
well plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 300 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 300 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
L3.3 co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: L3.3 cells (Academic Laboratory) are grown to 90% confluence in DMEM, 10% 
FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (1500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
 
! 9!
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 300 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 300 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 
per well.  
 
RVH-421 co-treatment cytotoxicity assay using CellTiter-Glo® 
Day 0: RVH-421 cells (RIKEN, RVH-421 ACC127) are grown to 90% confluence in 
RPMI-1640, 10% FBS, 1% Pen-Strep-Glut.   
Day 1: Plate cells (2500 per well) in 40 μl of culturing media using Corning® 384-well 
plate and incubate for 24 hours at 37°C in a 5% CO2 and 95% humidity incubator.  
Day 2: Dilute the stock Trequinsin and Cilostamide using a serial dilution to obtain 
concentrations ranging from 10 mM to 1 μM of drug in DMSO. Dilute each 
concentration of a log and half-log serial dilution of compound by 1:200 in culturing 
media containing Compound 1B EC90 of 30 nM, observed in the preliminary cytotoxic 
screening. Further dilute 1:5 by adding 10 μL of the drug into the designated 40 μL 
plated well (50 μl total volume). Perform at least 8 replicates per concentration per drug. 
The final dilution of Trequinsin and Cilostamide will be in the range of 10 μM – 0.3 nM, 
while the final concentration of Compound 1B will be a constant 30 nM.  
Day 4: Remove the 384-well plate from the incubator and allow to cool for 30 minutes to 
room temperature. Add 40 μl of a 25% Promega CellTiter-Glo® solution (diluted 1:3 
with room temperature PBS) with Rainin multichannel and incubate for 10 minutes at 
room temperature. Read on Perkin-Elmer EnVision with US LUM settings for 0.1 second 













































































































































































































































Supplementary Appendix, Figure S2: Compound 1B and analogue treatment 
cell viability curves.  
  
   
   





































































































































































































Supplementary Appendix, Figure S3: Compound 1B and PDE3 inhibitor co-






Supplementary, Appendix,, Figure, S3:! Compound, 1B, and, PDE3, inhibitor, co7treatment, cell, viability,
curves., 8505C,, CAS)1,,HuT)78,, JHOM)1,, L3.3,! and! RVH)421!were! subjected! to! Compound! 1B! and! non)
lethal!PDE3!inhibitors,!Trequinsin!or!Cilostamide!(0.3!nM!)!10!mM),!for!48H.,Error!bars!represent!S.D.!of!






































































































Supplementary Appendix, Table S1: PDE 3 selective inhibitors.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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